“Corramycin2 is a siderophore-conjugate of an analogue of Corramycin, a novel antibacterial natural product discovered by Sanofi and that possesses a brand-new scaffold, an original MoA and an unprecedented mode of uptake in Gram-negative bacteria. Corramycin2 stems from an optimization program starting from Corramycin. Corramycin2 constitutes the first representative of a novel class of antibacterial that could bring a new injectable treatment option to patients suffering from severe hospital infections caused by antibiotic resistant Gram-negative pathogens.
In this poster, we:
Read our poster to learn more about our research!